A new minimally invasive open pelvic lymphadenectomy surgical technique for the staging of prostate cancer

Urology

Volumn 47, Issue 3, 1996, Pages 416-421

  Brant, Leonard A ^a   Brant, William O ^a   Brown, Michael H ^a   Seid, Derald L ^a   Allen Jr , Robert E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SURGICAL TECHNIQUE;

EID: 0030000440     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80464-6     Document Type: Conference Paper

References (56)

1. Wingo PA, Tong T, and Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45: 8-30, 1995.
2. Ries LA, Miller BA, Hankey BF, Kosary CL, Harras A, Devesa SS, and Edwards BK: SEER Cancer Statistics Review, 1973-1990: Tables and Graphs, National Cancer Institute. NIH, Bethesda, MD, 1993.
3. Shurbaji MS, Kalbfleisch JH, and Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 26: 106-109, 1995.
4. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, and Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1669, 1993.
5. Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, Thompson TC, and Scardino PT: Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 151: 1301-1307, 1994.
6. Adolfsson J, Rönström L, Hedlund PO, Löwhagen T, Carstensen J, and Tribukait B: The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer. J Urol 144: 1404-1407, 1990.
7. Sumiya H, Masai M, Akimoto S, Yatani R, and Shimazaki J: Histochemical examination of expression of ras p21 protein and R1881-binding protein in human prostatic cancers. Eur J Cancer 26: 786-789, 1990.
8. Harper ME, Goddard L, Wilson DW, Matanhelia SS, Conn IG, Peeling WB, and Griffiths K: Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate 21: 75-84, 1992.
9. Muller JG, Demel S, Wirth MP, Manseck A, Frohmuller HG, and Muller HA: DNA-ploidy, G2M-fractions and prognosis of stages B and C prostate carcinoma. Virchows Arch 424: 647-651, 1994.
10. Berner A, Waere H, Nesland JM, Paus E, Danielsen HE, and Fossa SD: DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/MO prostatic adenocarcinoma. Br J Urol 75: 26-32, 1995.
11. Lee JK, Stanley RJ, Sagel SS, and McClennan BL: Accuracy of CT in detecting intraabdominal and pelvic lymph node metastases from pelvic cancers. AJR Am J Roentgenol 131: 675-679, 1978.
12. Dinjens W, van der Weiden MM, Schroeder FH, Bosman FT, and Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56: 630-633, 1994.
13. Fox SB, Persad RA, Royds J, Kore RN, Silcocks PB, and Collins CC: p53 and c-myc expression in stage Al prostatic adenocarcinoma: useful prognostic determinants? J Urol 150: 490-494, 1993.
14. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, and Chung LW: Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45: 470-475, 1995.
15. Voeller HJ, Sugars LY, Pretlow T, and Gelmann EP: p53 oncogene mutations in human prostate cancer specimens. J Urol 151: 492-495, 1994.
16. Uchida T, Wada C, Shitara T, Egawa S, and Koshiba K: Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer. Br J Cancer 68: 751-755, 1993.
17. Gumerlock PH, Poonamallee UR, Meyers FJ, and deVere White RW: Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 51: 1632-1637, 1991.
18. Lloyd SN, Brown IL, and Leake RE: Ki-67 antibody immunostaining in benign and malignant human prostatic disease. Int J Biol Markers 7: 256-259, 1992.
19. Mukamel E, Hannah J, Barbaric Z, and deKernion JB: The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging. J Urol 136: 1231-1233, 1986.
20. Kozlowski JM, and Grayhack JT: Carcinoma of the prostate, in Gillenwater JY, Grayhack JT, Howards SS, and Ducken JW (Eds): Adult and Pediatric Urology. Chicago, Year Book Medical Publishers, 1991, pp 1127-1219.
21. Brendler CB, Cleeve LK, Anderson EE, and Paulson DF: Staging pelvic lymphandenectomy for carcinoma of the prostate: risk versus benefit. J Urol 124: 849-850, 1980.
22. McLaughlin AP, Saltzstein SL, McCullough DL, and Gittes RF: Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. J Urol 115: 89-94, 1976.
23. Golimbu M, Morales P, Al-Askari S, and Brown J: Extended pelvic lymphadenectomy for prostate cancer. J Urol 121: 617-620, 1979.
24. Grossman IC, Carpiniello V, Greenberg SH, Malloy TR, and Wein AJ: Staging pelvic lymphadenectomy for carcinoma of the prostate: review of 91 cases. J Urol 124: 632-634, 1980.
25. Paul DB, Loening SA, Narayana AS, and Culp DA: Morbidity from pelvic lymphadenectomy in staging carcinoma of the prostate. J Urol 129: 1141-1144, 1983.
26. Arduino LJ, and Glucksman MA: Lymph node metastases in early carcinoma of the prostate. J Urol 88: 91-93, 1962.
27. Babcock JR, and Grayhack JT: Morbidity of pelvic lymphadenectomy. Urology 13: 483-486, 1979.
28. McDowell GC 2d, Johnson JW, Tenney DM, and Johnson DE: Pelvic lymphadenectomy for staging clinically localized prostate cancer. Indications, complications, and results in 217 cases. Urology 35: 476-482, 1990.
29. Donohue RE, Mani JH, Whitesel JA, Augspurger RR, Williams G, and Fauver HE: Intraoperative and early complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. Urology 35: 223-227, 1990.
30. Patel MI, and Katelaris PM: Indications for laparoscopic pelvic lymph node dissection in the staging of prostate cancer. Aust N Z J Surg 65: 233-236, 1995.
31. Lieskovsky G, Skinner DG, and Weisenburger T: Pelvic lymphadenectomy in the management of carcinoma of the prostate. J Urol 124: 635-638, 1980.
32. Parra RD, Andrus C, and Boullier J: Staging laparoscopic pelvic lymph node dissection: comparison of results with open pelvic lymphadenectomy. J Urol 147: 875-378, 1992.
33. Schuessler WW, Vancaillie TG, Reich H, and Griffith DP: Transperitoneal endosurgical lymphadenectomy in patients with localized prostate cancer. J Urol 145: 988-991, 1991.
34. Winfield HN, Donovan JF, Seen WA, Loening SA, and Williams RD: Urological laparoscopic surgery. J Urol 146: 941-948, 1991.
35. Lang GS, Ruckle HC, Hadley HR, Lui PD, and Stewart SC: One hundred consecutive laparoscopic pelvic lymph node dissections: comparing complications of the first 50 cases to the second 50 cases. Urology 44: 221-225, 1994.
36. Bowsher WG, Clarke A, Clarke DG, and Costello AJ: Laparoscopic pelvic lymph node dissection for carcinoma of the prostate and bladder. Aust N Z J Surg 62: 634-637, 1992.
37. Thomas R, Steele R, Smith R, and Brannan W: One-stage laparoscopic pelvic lymphadenectomy and radical perineal prostatectomy. J Urol 152: 1174-1177, 1994.
38. Schuessler WW, Pharand D, and Vancaillie TG: Laparoscopic standard pelvic node dissection for carcinoma of the prostate: is it accurate? J Urol 150: 898-901, 1993.
39. Rukstalis DB, Gerber GS, Vogelzang NJ, Haraf DJ, Straus FH 2d, and Chodak GW: Laparoscopic pelvic lymph node dissection: a review of 103 consecutive cases. J Urol 151: 670-674, 1994.
40. Levy DA, and Resnick MI: Laparoscopic pelvic lymphadenectomy and radical perineal prostatectomy: a viable alternative to radical retropubic prostatectomy. J Urol 151: 905-908, 1994.
41. Guazzoni G, Montorsi F, Bergamaschi F, Bellinzoni P, Centemero A, Consonni P, and Rigatti P: Open surgical revision of laparoscopic pelvic lymphadenectomy for staging of prostate cancer: the impact of laparoscopic learning curve. J Urol 151: 930-933, 1994.
42. Burney TL, Campbell EC Jr, Naslund MJ, and Jacobs SC: Complications of staging laparoscopic pelvic lymphadenectomy. Surg Laparosc Endosc 3: 184-190, 1993.
43. Kerbl K, Clayman RV, Petros JA, Chandhoke PS, and Gill IS: Staging pelvic lymphadenectomy for prostate cancer: a comparison of laparoscopic and open techniques. J Urol 150: 396-398, 1993.
44. Stone NN, Ramin SA, Wesson MF, Stock R, Unger P, and Klein G: Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 153: 1555-1560, 1995.
45. Steiner MS, and Marshall FF: Mini-laparotomy staging pelvic lymphadenectomy (minilap). Alternative to standard and laparoscopic pelvic lymphadenectomy. Urology 41: 201-206, 1993.
46. Bishoff JT, Reyes A, Thompson IM, Harris MJ, St. Clair SR, Gomella L, and Butzin CA: Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology 45: 270-274, 1995.
47. Sullivan LD, and Rabbani F: Should we reconsider the indications for ileo-obturator node dissection with localized prostate cancer? Br J Urol 75: 33-37, 1995.
48. Narayan P, Fournier G, Gajendran V, Leidich R, Lo R, Wolf JS Jr, Jacob G, Nicolaisen G, Palmer K, and Freiha F: Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 44: 519-524, 1994.
49. Chandhoke PS: Re: Laparoscopic pelvic lymph node dissection: a review of 103 consecutive cases. J Urol 152: 1214-1215, 1994.
50. Danella JF, deKernion JB, Smith RB, and Steckel J: The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 149: 1488-1491, 1993.
51. Wolf JS Jr, Shinohara K, Kerlikowske KM, Narayan P, Stoller ML, and Carroll PR: Selection of patients for laparoscopic pelvic lymphadenectomy prior to radical prostatectomy: a decision analysis. Urology 42: 680-688, 1993.
52. Troxel S, and Winfield HN: Comparative financial analysis of laparoscopic versus open pelvic lymph node dissection for men with cancer of the prostate. J Urol 151: 675-680, 1994.
53. Bratt O, Elfving P, Flodgren P, and Lundgren R: Morbidity of pelvic lymphadenectomy, radical retropubic prostatectomy and external radiotherapy in patients with localised prostatic cancer. Scand J Urol Nephrol 28: 265-271, 1994.
54. Flowers JL, Feldman J, and Jacobs SC: Laparoscopic pelvic lymphadenectomy. Surg Laparosc Endosc 1: 62-70, 1991.
55. Kavoussi LR, Sosa E, Chandhoke P, Chodak G, Clayman RV, Hadley HR, Loughlin KR, Ruckle HC, Ruckstalis D, Schuessler W, et al: Complications of laparoscopic pelvic lymph node dissection. J Urol 149: 322-325, 1993.
56. Parra RD, Andrus CH, and Boullier JA: Staging laparoscopic pelvic lymph node dissection. Experience and indications. Arch Surg 127: 1294-1297, 1993.